Brucein D suppresses breast cancer proliferation and migration via targeting the FAK/LRG1 signaling pathway Authors: Lin Li, Haoyang Shen, Yu Qiu, Yan Chen, Weizhu Wu Published: 2025 ABSTRACT AbstractBreast cancer (BC) is a leading cause of cancer-related mortality in women worldwide, underscoring the need for novel therapeutic strategies. Focal adhesion kinase (FAK) has emerged as a promising oncological target due to its central role in tumor progression. Bruceine D (BD), a natural compound from Brucea javanica, exhibits anti-cancer properties, but its mechanism in BC via FAK inhibition remains unclear. We conducted a comprehensive investigation using BC cell lines. Cell viability and migration were assessed by MTT and transwell assays, respectively. The tube formation assay examines the effect of BD on angiogenesis. Mitochondrial function was evaluated by measuring reactive oxygen species (ROS), ATP production, and mitochondrial membrane potential (ΔΨm). Apoptosis was quantified via flow cytometry. RNA sequencing (RNA-seq) with pathway enrichment analysis was employed to identify FAK-associated signaling pathways, and key protein expression changes, including FAK and downstream factors, were validated by western blotting. BD significantly suppressed BC cell proliferation, migration, and angiogenesis by inducing mitochondrial dysfunction, characterized by elevated ROS levels, depleted ATP, and loss of ΔΨm. Clinical analysis confirmed FAK overexpression in BC tissues. Mechanistically, BD inhibited FAK signaling. RNA-seq further revealed that FAK inhibition modulated several downstream pathways, including the expression of LRG1, collectively leading to the induction of apoptosis. This study identifies BD as a potent small-molecule FAK inhibitor. Our findings delineate a FAK-centered mechanism of action for BD, supporting its further development as a promising therapeutic agent for BC.Supplementary InformationThe online version contains supplementary material available at 10.1038/s41598-025-31943-w.Keywords: Breast cancer, Brucein d, FAK, LRG1, Cell proliferation, Cell migrationSubject terms: Cancer, Cell biology, Drug discovery, Oncology Introduction Breast cancer (BC) remains the most frequently diagnosed malignancy and the leading cause of cancer-related death among women worldwide. According to the latest global cancer statistics from the WHO International Agency for Research on Cancer (IARC), BC has surpassed lung cancer as the most commonly diagnosed cancer, with an estimated 2.3 million new cases and 670,000 deaths from BC occurred in 20221,2. The global BC burden shows significant geographic disparity, with incidence rates highest in developed regions like Australia/New Zealand and mortality rates highest in developing regions like Melanesia and Western Africa. This inequity is underscored by a sharp increase in the mortality-to-incidence ratio as the Human Development Index (HDI) decreases, rising from 17% in very high HDI regions to 56% in low HDI regions1. Although current treatment strategies—including surgery, chemotherapy, radiotherapy, hormone therapy, and biological therapy—have demonstrated efficacy in managing BC3, they often result in poor prognosis due to the complex etiology of BC and the development of drug resistance. In recent years, targeted therapy has gained widespread attention for its potential to overcome resistance mechanisms that cancer cells develop against conventional chemotherapy4. While such approaches have improved outcomes in several cancers, including BC, the emergence of drug resistance remains a major clinical challenge. There is thus an urgent need to identify novel therapeutic targets and agents for more effective BC treatment. Focal adhesion kinase (FAK), a non-receptor tyrosine kinase, is frequently overexpressed in a variety of aggressive and metastatic cancers, including BC5,6. As a central signaling node, FAK regulates multiple cellular processes such as proliferation, adhesion, migration, and survival through its involvement in numerous oncogenic pathways. Its overexpression is strongly correlated with advanced disease stage and poor clinical prognosis, highlighting FAK as a compelling molecular target for anticancer therapy7. Nowadays, several small-molecule FAK inhibitors, including Conteltinib, Defactinib, and GSK2256098, have been developed, with Conteltinib showing promise in phase I trials for ALK-positive NSCLC; however, none have yet received regulatory approval8,9. This clinical translation failure can be attributed to several fundamental limitations: high toxicity profiles observed in early-phase trials due to mechanism-based off-target effects, poor oral bioavailability that compromises therapeutic efficacy, and the rapid development of resistance mechanisms through compensatory pathway activation10. This reflects both the considerable therapeutic potential of FAK inhibition and the ongoing challenges in effectively targeting this kinase in human cancers. The diverse oncogenic functions of FAK have spurred growing research interest in its downstream effectors. Among these, leucine-rich alpha-2-glycoprotein 1 (LRG1) has attracted considerable attention for its role in cancer biology. Initially identified in human serum, LRG1 has emerged as a protein of increasing interest in oncology research11. LRG1 frequently upregulated in multiple malignancies, including BC and its elevated expression is often associated with cancer progression and poor prognosis12. LRG1 is now known to participate in immune regulation, cell proliferation, metastasis, and apoptosis13. Research indicates that intracellular LRG1 promotes BC cell survival by directly binding to and protecting cytochrome c, thereby helping these cells resist apoptosis14. Although studies have indicated that LRG1 promotes ovarian cancer progression by regulating the FAK/AKT signaling pathway15, the precise upstream-downstream relationship between FAK and LRG1 remains unclear. Given this broader context, we hypothesize that the FAK-LRG1 axis represents a critical oncogenic signaling cascade. Consequently, vertically inhibiting this axis may be a viable strategy to more effectively block BC progression. Natural products and active compounds derived from traditional Chinese medicine have long served as valuable sources for drug discovery. Brucea javanica is a recognized medicinal plant in China, historically used to manage a range of ailments, including intestinal inflammation, dysentery, malaria, and cancer16,17. Bruceine D (BD), a quassinoid compound isolated from Brucea javanica (L.) Merr. exhibits notable pharmacological versatility, including anti-inflammatory, antiviral, and anticancer activities18. Preclinical studies have demonstrated that it exhibits significant anti-cancer efficacy in models of lung cancer19, liver cancer20, osteosarcoma21, and BC22. As a naturally occurring product, BD may offer distinct advantages over synthetic inhibitors, including a more favorable safety profile and multi-targeting capabilities that could enhance efficacy and mitigate resistance. Despite these challenges in translational development, such as extraction yields, pharmacokinetics, and in vivo validation, BD’s broad anti-cancer activity provides a compelling rationale for further investigation. Therefore, this study aims to elucidate the previously unexplored link between BD and FAK inhibition in BC. We identify BD as a novel FAK inhibitor and demonstrate for the first time, that it suppresses the FAK/LRG1 signaling axis to promote BC cell apoptosis. These findings not only clarify BD’s mechanism of action but also position it as a promising therapeutic candidate capable of overcoming limitations of existing targeted therapies. Methods Cell culture The human BC cell lines MCF-7 and MDA-MB-231 were acquired from the Chinese Academy of Sciences and Shanghai Institute of Biological Sciences. These cell lines were grown in Dulbecco’s Modified Eagle Medium (DMEM, Gibco, USA), which was supplemented with 10% fetal bovine serum (FBS, Gibco, USA) and 1% penicillin-streptomycin antibiotic solution (Beyotime, China). The cells were incubated at 37 °C in a humidified atmosphere containing 5% CO2. To maintain phenotypic stability and ensure experimental reproducibility, all experiments utilizing BC cell lines were conducted with cells within 20 passages, while normal cell lines were used within 10 passages. Reagents and antibodies Brucein D (TWS2045) was purchased from Innochem (the purity is 99%) and dissolved in DMSO for use. BD was dissolved in DMSO to prepare a 10 mM stock solution, which was aliquoted and stored at −20 °C. For all subsequent experiments, this stock was then diluted with culture medium to ensure that the final concentration of DMSO in any treatment well did not exceed 0.01%. The ROS Assay Kit (S0033M) and ATP Assay Kit (S0026) were obtained from Beyotime (Shanghai, China). The MTT (GC307004), Annexin V-FITC Apoptosis Assay Kit (G1511), and Mitochondrial Membrane Potential Assay Kit were obtained from Solarbio (Beijing, China). The primary antibodies against p-FAK (3283 S) were purchased from CST. FAK (12636-1-AP) was obtained from Proteintech. The E-cadherin (YT1454), N-cadherin (YM0465), BAX (YT0455), Cleaved-caspase 3 (YC0006), p-AKT (YP0006), AKT (YT0185), and mTOR (YT2913) were obtained from Immunoway. The primary antibodies against p-mTOR (AF5869), 53BP1 (AF6111), Snail (AF8013), and BCL-2 (AG1222) were purchased from Beyotime. The p-PI3K (AP0427), PI3K (A11177), p-Src (AP1027), Src (A19119), MMP9 (A0289), and LRG1 (A7850) were obtained from (ABclonal). Secondary antibodies, including anti-rabbit IgG (No. 7074) and anti-mouse IgG (No. 7076), were purchased from Cell Signaling Technology (USA). All reagents and antibodies were stored according to the instructions. Cell viability assay To evaluate the inhibitory effects of BD on BC and MIHA cell proliferation, cells were plated in 96-well plates at a density of 8 × 10³ cells per well and allowed to adhere overnight. Following attachment, the cells were treated with varying concentrations of BD for 48 h. After the incubation period, 20 µL of MTT solution (5 mg/mL) was added to each well, and the plates were further incubated at 37 °C in a 5% CO₂ atmosphere for 4 h. The culture medium was then carefully aspirated, and 100 µL of DMSO was added to solubilize the formazan crystals. Finally, the OD at 490 nm was measured using a microplate reader to determine cell viability23. Colony formation assay For colony formation analysis, MCF-7, MDA-MB-231, and MIHA cells were seeded in 12-well plates at a density of 1 × 10³ cells per well and cultured overnight to ensure proper attachment. The cells were then exposed to increasing concentrations of BD (0.5, 1.0, and 2.0 µM) and maintained in a 37 °C, 5% CO₂ incubator for 7 days to allow colony development. Following incubation, the resulting colonies were gently washed with PBS, fixed with 4% paraformaldehyde solution for 15 min, and subsequently stained with 0.1% crystal violet solution for 10 min at ambient temperature. After washing three times with distilled water, colonies in each plate were observed under a light microscope24. Transwell assay Cell migration was assessed using a 24-well Transwell system (Corning, USA). Following treatment, BC cells were trypsinized, resuspended, and diluted in serum-free medium to a final concentration of 1 × 10⁶ cells/mL. The lower chamber was filled with 600 µL of medium containing 10% FBS as a chemoattractant, while 100 µL of cell suspension was added to the upper chamber. After 24 h of incubation at 37 °C, non-migrated cells were removed from the upper chamber, and the membrane was washed three times with PBS. Migrated cells on the lower surface were fixed with 4% paraformaldehyde (15 min, RT) and stained with 0.1% crystal violet. Excess stain was rinsed with distilled water, and imaged with an inverted fluorescence microscope25. Immunofluorescence (IF) assay BC cells grown on coverslips were fixed with 4% paraformaldehyde and permeabilized with 0.25% Triton X-100 in PBS. Subsequently, the cells were blocked with 5% bovine serum albumin (BSA) for 2 h at room temperature. Following blocking, the samples were incubated overnight at 4 °C with primary antibodies against FAK and 53BP1 at dilutions of 1:400 and 1:200, respectively. After washing, the cells were probed with corresponding DyLight-conjugated secondary antibodies (1:500) for 1.5 h at room temperature. Finally, the nuclei were counterstained with DAPI, and the coverslips were mounted onto glass slides. Fluorescence images were acquired using an Olympus fluorescence microscope. Determination of intracellular reactive oxygen species (ROS) Intracellular ROS levels were assessed using the Reactive Oxygen Species Assay Kit (Beyotime, China). Briefly, BC cells were seeded in 6-well plates at a density of 4 × 10⁵ cells per well and allowed to adhere overnight. After attachment, the cells were treated with BD at varying concentrations (0.5, 1.0, and 2.0 µM) for 2 h. Subsequently, the cells were incubated with 10 µM DCFH-DA at 37 °C for 20 min. The intracellular ROS levels were measured using the fluorescent probe DCFH-DA, with fluorescence visualized under an inverted fluorescence microscope (Olympus). The excitation and emission wavelengths were set at 488 nm and 525 nm, respectively, and a FITC filter set was used for image acquisition. The fluorescence intensity of ROS signals was quantified using ImageJ software. ATP content detection assay To quantify cellular ATP levels in BC cells, we performed measurements using a commercial firefly luciferase-based ATP assay kit (Beyotime, China) according to the manufacturer’s protocol. Briefly, cells were lysed with ice-cold lysis buffer, followed by centrifugation to collect the supernatant. Both standard ATP solutions and cellular supernatants were aliquoted into 96-well white opaque plates. Subsequently, 100 µL of detection buffer was added to each well. All samples were standardized against total protein concentration. Luminescence signals (RUL) were measured using a Bio-Tek Synergy H1 fully integrated microplate reader, and ATP concentrations were determined by interpolation from a standard curve generated with known ATP concentrations. Assessment of mitochondrial membrane potential (MMP) Mitochondrial membrane potential (ΔΨm) was assessed using the JC-1 Mitochondrial Membrane Potential Assay Kit (Beyotime, China) following the manufacturer’s instructions. Briefly, BC cells treated with BD were washed twice with ice-cold dilution buffer and then incubated with JC-1 dye (5 µg/mL) at 37 °C for 30 min in the dark. After two additional washes with dilution buffer, fluorescence images were acquired using an Olympus fluorescence microscope. The ratio of red-to-green fluorescence intensity was quantified to determine ΔΨm changes, where a decrease indicates mitochondrial depolarization. Cell apoptosis Apoptosis was analyzed using a FITC Annexin V Apoptosis Detection Kit (BD Biosciences, San Jose, CA, USA). Briefly, BC cells were cultured in 6-well plates and treated with BD at varying concentrations (0.5, 1.0, and 2.0 µM) for 48 h. After treatment, cells were harvested, washed twice with ice-cold PBS, and resuspended in 1× Binding Buffer. Subsequently, 5 µL of propidium iodide (PI) and 5 µL of FITC Annexin V were added to the cell suspension, followed by a 15 min incubation in the dark at room temperature. Finally, 400 µL of 1× Binding Buffer was added to each sample, and apoptotic cell populations were quantified using flow cytometry (BD FACSCanto™ II). For each experimental group, 10,000 cells were collected to ensure statistical reliability for subsequent analysis and graphical representation26. Western blot (WB) analysis The MCF-7 and MDA-MB-231 cells and tumor tissues were homogenized and then lysed in RIPA lysis buffer containing 1% phosphatase inhibitor and PMSF for 10 min at 4 °C. The lysates were collected and protein concentrations were measured using the Bradford assay (Bio-rad, Hercules, CA). Protein samples were separated by electrophoresis on 10% SDS-PAGE gels and transferred to polyvinylidene difluoride (PVDF) membranes. The blots were blocked for 2 h at room temperature with 5% nonfat milk in TBST and then incubated with specific primary antibodies (1:1000 dilution) overnight at 4 °C. After washing, the membranes were incubated with HRP-conjugated secondary antibody (1:2000 dilution) for 1.5 h at room temperature. GAPDH was used as the loading control for all markers. Finally, the protein bands were visualized and photographed using the ECL substrate for detection25. Human subjects Human BC tissue samples were obtained from the Department of Breast Surgery at Ningbo Medical Center Lihuili Hospital. This study collected five pairs of cancerous and adjacent normal tissue samples from BC patients who had not received any treatment before surgery. Both cancerous and adjacent normal tissues from all patients were obtained by professional surgeons through surgical procedures, and written informed consent was obtained from each patient before surgery. The study was conducted in strict accordance with the ethical principles outlined in the Declaration of Helsinki (1975) and received formal approval from the Institutional Ethics Committee of Ningbo Medical Center Lihuili Hospital (Approval No: KY2023PJ289). TCGA database analysis RNA-seq STAR-counts data and corresponding clinical information for BC were obtained from The Cancer Genome Atlas (TCGA) database (https://portal.gdc.cancer.gov). The data were then converted to Transcripts Per Million (TPM) format and normalized using log2(TPM + 1). Samples with concurrent RNA-seq data and complete clinical annotations were retained for subsequent analysis. Additionally, genotype-tissue expression (GTEX) data from the V8 release were included, with detailed information accessible at the GTEx Portal (https://gtexportal.org/home/datasets). All statistical analyses were performed using R software (version 4.0.3). A P-value of less than 0.05 was considered statistically significant. Prognosis analysis Data were obtained from The Cancer Genome Atlas (TCGA; https://portal.gdc.cancer.gov), comprising STAR-counts RNA-seq data and clinical information for BC, wherein expression values were transformed to TPM, normalized via log₂(TPM + 1), and filtered to retain samples with complete datasets. Survival analyses were performed using Kaplan-Meier curves, with between-group comparisons conducted by the log-rank test. Associated hazard ratios with 95% confidence intervals and P-values were calculated via univariate Cox regression. All statistical operations were executed using R software version 4.0.3, adopting a significance threshold of P < 0.05. Immunohistochemistry (IHC) According to the guidelines of the Li Huili Hospital Ethics Committee, the surgically resected BC and adjacent tissue samples were divided into two groups: one for histomorphological analysis, which involved fixation in 10% neutral buffered formalin at room temperature for 48 h, followed by paraffin embedding and sectioning into 5-µm-thick serial slices; the other was archived in the Pathology Center as per regulations for subsequent research. All procedures were strictly performed in accordance with established protocols. For IHC staining, antigen retrieval was performed using citric acid solution. Tissue sections were then incubated overnight at 4 °C with primary antibodies against FAK (dilution 1:200), followed by treatment with HRP-conjugated secondary antibodies (1:500) for 1.5 h at 37 °C. Immunoreactivity was visualized using DAB chromogen, resulting in characteristic brownish-yellow deposition in positive cells. The stained sections were examined under a Nikon Eclipse E200 light microscope, and FAK protein expression was observed to be localized in either the nucleus or cytoplasm. Photomicrographs were captured using an inverted microscope, followed by quantitative analysis of the immunohistochemical results with ImageJ software by calculating the percentage of positive cells. Drug affinity responsive target stability (DARTS) BC cells were lysed in RIPA lysis buffer (containing protease and phosphatase inhibitors) on ice for 10 min. After centrifugation at 4 °C at 12,000×g for 15 min, the clear cell lysate was collected and aliquoted. The lysate was then treated with different concentrations of BD (0.5, 1.0, and 2.0 µM) at room temperature under gentle agitation for 40 min. Following incubation, an appropriate volume of thermophilic protease was added, and the mixture was incubated at 37 °C for 20 min. Samples were subsequently subjected to heat-lysing at 100 °C for 10 min to complete protein denaturation. After a final centrifugation (12,000 × g, 10 min, 4 °C), collect the supernatant and analyze it by Western blotting27. Solvent-induced protein precipitation (SIP) assay The BC cells’ lysates were collected and incubated with 10 µΜ of BD for 50 min. Then, the cell lysates were incubated with the indicated solvent volume containing acetone-ethanol-acetic acid (AEA) (50:50:1) for 30 min. After centrifugation, the supernatant was collected and analyzed by Western blotting assay. Molecular docking The crystal structure of FAK was obtained from the Protein Data Bank (PDB ID: 4gu9). Prior to docking, all non-essential water molecules were removed from the protein structure, and both the ligand and receptor structures underwent energy minimization using the CHARMm force field. Molecular docking studies were performed using the CDOCKER protocol within BIOVIA Discovery Studio 4.5 Client. CDOCKER is a CHARMm-based docking algorithm capable of producing highly accurate docking results. The binding poses were primarily evaluated by the CDOCKER_ENERGY scoring function to report interaction energies. This rigorous protocol ensures the reliability and accuracy of our docking results. Transient transfection of small interfering RNA (siRNA) The siRNA targeting human FAK was purchased from Tsingke Biotechnology (Beijing, China) with the following sequence: siNC: 5- UUCUCCGAACGUGUCACGU-3; siFAK: 5-GGGCAUCAUUCAGAAGAUATT-3. Human BC cells were transfected with 50 nM siRNA using Lipofectamine RNAiMAX (Invitrogen, CA, USA) for 12 h. Statistical analysis Statistical analysis was performed with GraphPad Prism 9.0 software. All the results were performed at least three times. One-way ANOVA followed by Dunnett’s post hoc test is used when comparing more than two data groups. A p-value < 0.05 was considered statistically significant28. Results BD inhibits BC cell proliferation, migration, and angiogenesis To determine the cytotoxicity of BD, the MCF-7 and MDA-MB-231 cells were subjected to BD treatment at various concentrations, and cell viability was examined via the MTT assay. The structure of BD is shown in Fig. 1A. The MTT results confirmed that BD is capable of reducing cell viability in a dose-dependent manner (Fig. 1B and C). Importantly, we also evaluated the effect of BD on the viability of normal liver cells. The results showed that MIHA cells maintained higher viability than BC cells even when treated with 100 µM BD. Furthermore, the IC50 values for the three cell lines revealed that BD was 5.1 ± 1.1, 5.7 ± 1.1, and 46.7 ± 3.0 µM against MCF-7, MDA-MB-231, and MIHA cells, respectively, indicating a favorable safety profile (Fig. 1D; Table 1). The colony formation assay not only confirmed that 2.0 µM BD effectively suppressed colony formation in BC cells, but also revealed that its inhibitory effect on MIHA normal liver cells was significantly weaker than on cancer cells. This suggests that BD may exert a selective inhibitory effect on BC cells (Fig. 1E). Cell metastasis is a complex process of tumor development involving cell migration. Here, the effects of BD on the migration of MCF-7 and MDA-MB-231 cells were examined by transwell assay. Our results demonstrated that BD dose-dependently inhibited the migration of BC cells, while exhibiting a markedly weaker inhibitory effect on the migration of MIHA cells (Fig. 1F). EMT could decrease intercellular adhesion and enhance cell motility, leading to cancer cell metastasis and promoting cancer development. Therefore, we detected the changes in such protein expressions in BC cells. We found that the expression of E-cadherin was upregulated, while N-cadherin (N-cadherin is not expressed in MCF-7 cells), MMP9, and Snail were downregulated (Fig. 1G). Additionally, BD possesses the ability to disrupt angiogenesis (Fig. 1H). In summary, BD possesses the ability to inhibit BC cell proliferation, migration, and angiogenesis. BD inhibits BD cell proliferation, migration, and angiogenesis. (A) The chemical structure of BD. (B-D) The effect of BD on the survival rates of MCF-7, MDA-MB-231, and MIHA cells. (E) Colony formation assay in BC and MIHA cells treated with the indicated concentrations of BD. (F) Transwell assay was used to measure the effect of BD on the migration of BC and MIHA cells (200×). (G) Western blot assays of E-cadherin, N-cadherin, MMP9, and Snail protein expression levels in BD-treated BC cells and normal controls at indicated doses (0.5, 1.0 and 2.0 µM) for 48 h. GAPDH was set as an internal loading control. Full-size blots are presented in original western blot bands. (H) The effect of BD on angiogenesis capacity (40×). The average ± SD of three independent assessments was used to calculate the values. **P < 0.01, ***P < 0.001 vs. control group. Table 1Half-maximal inhibitory concentrations (IC50) of BD determined using MTT assay.Cell linesIC50(µM)MCF-75.1 ± 1.1MDA-MB-2315.7 ± 1.1MIHA46.7 ± 3.0 Half-maximal inhibitory concentrations (IC50) of BD determined using MTT assay. BD promotes DNA damage and disrupts mitochondrial biological function Natural products often exert their anti-cancer effects by inducing DNA damage and disrupting mitochondrial biological function. Therefore, we conducted an IF assay using 53BP1 antibody, which has been used as a marker for DNA double-stained breaks to verify BD could promote DNA damage. Our results suggested that BD dose-dependently increased the number of 53BP1 foci in the BC cells (Fig. 2A). Notably, compared to the control group, 2.0 µM BD induced approximately 18 DNA damage foci in both MCF-7 and MDA-MB-231 cells (Fig. 2B and C). Mitochondria provide an energetic basis for the unlimited proliferation of cancer cells. Therefore, we examined the effect of BD on ATP production in BC cells. Our results confirm that 2.0 µM BD reduces ATP production in BC cells to 0.51 ± 0.09 and 0.44 ± 0.05 compared to the control group (Fig. 2D and E). Insufficient ATP production generates excess ROS and destroys mitochondrial membrane potential. Then, we used DCFH-DA and JC-1 fluorescent staining to detect ROS accumulation and MMP changes in BC cells. As shown in Fig. 2F and H, we found that after BD treatment, the ROS of BC cells was up-regulated dose-dependent. Additionally, treatment with BD decreased the MMP (Fig. 2I and J). BD promotes DNA damage and disrupts mitochondrial biology. (A) Representative images of 53BP1 foci in BC cells treated with the indicated concentrations of BD (400×). (B, C) Quantification of the 53BP1 foci per cell. More than 100 cells were counted in each group. (D, E) The effect of ATP levels in BC cells after BD treatment. (F) Intracellular ROS as detected by DCFH-DA staining (green, 400×). (G, H) Quantification of ROS fluorescence intensity. (I, J) JC-1 was used to detect the MMP of BC cells. J-aggregates (red) and JC-1 monomers (green) were detected (400×). The average ± SD of three independent assessments was used to calculate the values. *P < 0.05, **P < 0.01, ***P < 0.001 vs. control group. BD induces BC cell apoptosis by disrupting the mitochondrial biological functions Disruption of mitochondrial function leads to cell apoptosis. We further detected cell apoptosis in BC cells by Hochest staining. We found that BD-treated cells exhibited significant nuclear shrinkage and nuclear fragmentation, which implies that BD caused apoptosis of BC cells (Fig. 3A). Consistent with the Hochest staining results, we also found that BD treatment promoted cell apoptosis dose-dependently, and 2.0 µM BD caused apoptosis in about 31.8 ± 1.1% and 29.8 ± 4.6% of BC cells (Fig. 3B to D). Meanwhile, the well-known apoptosis-related proteins, including cleaved-caspase 3, BAX, and Bcl2, which are widely regarded as apoptosis markers, were chosen in the western blot assay. We found that BD decreased the expression of Bcl2 and increased the expression of cleaved-caspase 3 and BAX (Fig. 3E and F). The results further indicated that BD induces cell apoptosis by disrupting the mitochondrial biological functions. BD induces BC cell apoptosis by disrupting the mitochondrial biological functions. (A) The Hochest staining was used to detect BC cell apoptosis levels (200×). (B) BC cells were treated with BD at indicated concentrations for 48 h, and apoptotic cells were assayed by Annexin V/PI staining and FACS analysis. (C, D) Quantification of apoptosis by flow cytometry. (E, F) Western blot determined the abundance of BAX, Bcl-2, and CL-caspase 3 in control and BD-treated BC cells at the indicated concentrations. Full-size blots are presented in original western blot bands. The average ± SD of three independent assessments was used to calculate the values. **P < 0.01, ***P < 0.001 vs. control group. FAK is a predictive marker of BC progression and prognosis To investigate the anti-BC mechanisms of BD, we performed RNA-seq (The sequencing depth was 6 Gb per sample, and gene expression was normalized using the FPKM method) to analyze the global gene expression profiles in BD-treated MCF-7 cells compared to untreated controls. KEGG pathway analysis identified cell adhesion, molecular, and focal adhesion as key pathways modulated by BD treatment (Fig. 4A). Interestingly, FAK exhibits close interactions with both molecules. Several studies reported that FAK was associated with the development and progression of various human cancers, whereas inhibition of FAK could attenuate cancer progression. Therefore, it is reasonable to assume that FAK could be a potential therapeutic target against BC. To validate the hypothesis, we analyzed data from the TCGA database. Our results revealed that BC patients with high FAK expression exhibited a lower overall survival rate, and the HR rate is 1.616 (Fig. 4B and C). Importantly, following immunohistochemical analysis of clinical BC samples, we observed that FAK distribution and expression levels were higher in patient-matched tissue samples compared to tumor-adjacent tissue, with values of 37.7 ± 4.3 and 28.0 ± 2.7, respectively. Western blot results further corroborated these findings. These results align with data from the TCGA database (Fig. 4D and E). FAK is a predictive marker of BC progression and prognosis. (A) KEGG enrichment analysis of the control group and the BD treatment group. (B) Relative gene expression of FAK in BC samples. (C) Overall survival of BC patients with up- and down-regulated FAK expression levels. (D) Immunohistochemical staining of FAK levels in patient-matched and tumor-adjacent normal controls of BC (200×). (E) Western blot analysis of FAK protein levels in different BC tissues. (F and G) IF assay was used to detect the effect of BD on FAK distribution in BC cells (400×). (H) Western blot analysis of FAK and p-FAK protein levels in BD treated BC cells. (I) Western blot analysis of Src and p-Src protein levels in BD treated BC cells. Full-size blots are presented in original western blot bands. The average ± SD of three independent assessments was used to calculate the values. **P < 0.01, ***P < 0.001 vs. normal group. We next explore whether BD exerts its anti-BC effects by targeting FAK. In this study, we use IF and western blotting analyses to examine the effect of BD on the expression of FAK. Compared with untreated cells, BD-treated BC cells exhibited reduced FAK distribution, with localization to the cell nucleus (Fig. 4F and G), and BD dose-dependently decreased the expression of phosphorylated FAK in BC cells (Fig. 4H). Importantly, our results demonstrate that BD reduces the expression of phosphorylated Src in BC cells. This indicates that BD disrupts the formation of the FAK-Src complex, preventing Src from being fully activated (Fig. 4I). FAK was a therapeutic target in BC cells Given that BD significantly reduced FAK phosphorylation and its expression effectively inhibited BC cell proliferation and migration, we hypothesized that BD exerts its anti-BC activity through direct binding to FAK. To test this hypothesis, we first employed molecular docking analysis. The results showed that BD forms stable hydrogen bonds with key FAK residues (LYS-454, GLN-432, and ASP-564; Fig. 5A), and the binding energy of the BD-FAK complex was − 63.6383 kcal/mol. Molecular dynamics simulations using the NPT ensemble were conducted for 100 ns to validate the BD-FAK docking. The results indicate that the complex exhibits overall stability and rapidly reaches its equilibrium state (Fig. 5B). To further validate this interaction, we performed DARTS and SIP assays. The DARTS results demonstrated dose-dependent binding between BD and FAK (Fig. 5C), while SIP analysis indicated that BD treatment enhanced FAK stability in BC cells (Fig. 5D). The above results demonstrate a stable interaction between BD and FAK, and confirm that FAK can serve as a target for BD to exert its anti-BC effects. FAK was a therapeutic target in BC cells. (A) Putative binding modes of BD with FAK (4gu9). (B) Simulations of molecular dynamics (MD) with root-mean-square deviations (RMSD). (C) Immunoblotting for quantification of FAK level in drug affinity responsive target stability (DARTS) assay. (D) Immunoblotting for quantification of FAK level in solvent-induced protein precipitation (SIP) assay. Full-size blots are presented in original western blot bands. The average ± SD of three independent assessments was used to calculate the values. BD inhibits the proliferation and migration of BC cells through the FAK/LRG1 signaling axis Through further analysis of differentially expressed genes (|log2(foldchange)|>1, padj < 0.05), we found that the transcript level of LRG1 was significantly down-regulated, and thus speculated that LRG1 might be a downstream regulatory protein of FAK (Fig. 6A to C). To validate our hypothesis, we employed q-PCR and Western blot analysis. Experimental results demonstrated that both mRNA and protein expression levels of LGR1 were reduced in BD-treated BC cells, confirming our prediction. (Figure 6D and E). Evidence suggested that the PI3K/AKT/mTOR signaling pathway is the key intracellular signaling pathway of LGR129. As shown in Fig. 6F, the phosphorylated PI3K, AKT, and mTOR were decreased with an increasing BD concentration, while the PI3K, AKT, and mTOR levels remained unchanged. BD inhibits the proliferation and migration of BC cells through the FAK/LRG1 signaling axis. (A) Numbers of upregulated and downregulated genes identified by RNA-seq. (B) Volcano plot showing differentially expressed genes from RNA-seq data. (C) Relative LRG1 expression from transcriptome analysis. (D) Fold-change in LRG1 mRNA levels in BC cells after BD treatment. (E) Western blot analysis of LRG1 protein expression in BC cells treated with BD. (F) Western blot analysis was used to detect BD treatment in BC cells on PI3K/AKT/mTOR signaling pathway. (G) BC cells were treated with si-FAK combined with BD for 48 h, and the effect on proliferation ability was assessed. (H) BC cells were treated with si-FAK combined with BD for 48 h, and the effect on migration ability was assessed (200×). (I) Western blot analysis was used to detect the effect of FAK silencing and BD treatment in BC cells on FAK downstream LRG1, PI3K/AKT/mTOR signaling pathway. Full-size blots are presented in original western blot bands. The average ± SD of three independent assessments was used to calculate the values. **P < 0.01 vs. normal group. To delineate the functional role of the FAK/LRG1 axis in the anti-BC activity of BD, we performed FAK knockdown experiments in BC cells (Fig. S1). FAK silencing alone markedly suppressed the clonogenicity and migratory capacity of BC cells. Importantly, the combination of FAK knockdown and BD treatment exhibited a stronger inhibitory effect on these malignant phenotypes (Fig. 6G and H). Importantly, we detected changes in mitochondrial membrane potential after silencing FAK in BC cells. Results showed that mitochondrial membrane potential decreased following FAK silencing; when BD stimulation was applied to FAK-silenced BC cells, the decline in mitochondrial membrane potential became even more pronounced. This indicates that mitochondrial dysfunction is primarily caused by the massive ROS production induced by BD (Fig. S2). At the molecular level, FAK knockdown not only reduced the expression and phosphorylation of FAK but also led to subsequent downregulation of LRG1. The decrease in LRG1 was accompanied by compensatory suppression of the PI3K/AKT/mTOR pathway, as demonstrated by diminished phosphorylation levels. Crucially, in FAK-silenced BC cells, BD treatment resulted in more pronounced inhibition of both LRG1 and the PI3K/AKT/mTOR pathway compared to BD treatment alone (Fig. 6I). Collectively, our data demonstrate that BD exerts its anti-BC effects primarily by targeting FAK, thereby suppressing LRG1 and ultimately inhibiting the activation of the downstream PI3K/AKT/mTOR signaling pathway. Discussion This study elucidates a previously unrecognized mechanism through which BD suppresses BC progression via the FAK/LRG1 signaling axis-mediated mitochondrial dysfunction pathway, with particular emphasis on its profound anti-proliferative effects. Our findings not only provide novel pharmacological insights into BD’s anticancer activity but also establish a scientific foundation for the traditional use of Brucea javanica in cancer treatment. We confirmed BD’s significant anti-proliferative and anti-migratory effects in BC cells across multiple subtypes. BD, a bioactive natural product, exhibits potent anti-proliferative and anti-migratory activities against tumor cells. Studies have demonstrated that BD suppresses tumor cell migration by inhibiting the PI3K/AKT signaling pathway and the EMT process30,31. Additionally, previous studies have demonstrated that BD induces reactive oxygen species (ROS) accumulation in multiple cancer types; its precise upstream mechanisms remain poorly understood32,33. Our investigation revealed that BD primarily targets mitochondrial function, as demonstrated by the early collapse of MMP and subsequent ATP depletion. This mitochondrial impairment initiates a bioenergetic crisis that not only amplifies ROS generation but also directly limits the energy supply essential for cell proliferation, ultimately triggering apoptotic cell death. These findings not only corroborate previous observations of BD-induced ROS production but, more importantly, identify mitochondrial dysfunction as the initiating event in this cytotoxic cascade that fundamentally disrupts cellular proliferation. Our exploration of upstream signaling mechanisms focused on FAK, given its established role in cancer progression and potential involvement in redox regulation. The data demonstrate that BD significantly suppresses FAK phosphorylation in BC cells at concentrations achievable in preclinical models. FAK inhibition directly impacts cell proliferation through multiple pathways: first, it disrupts the FAK/PI3K/Akt/mTOR signaling axis, reducing protein synthesis and nutrient uptake34; second, it interferes with FAK-mediated integrin signaling that normally promotes cell cycle progression. Compared to synthetic FAK inhibitors, BD exhibits a unique dual mechanism by simultaneously targeting both FAK signaling and mitochondrial function, potentially offering therapeutic advantages in overcoming resistance mechanisms. A key advancement of our study lies in identifying LRG1 as a critical downstream effector in FAK-mediated signaling. Although LRG1’s oncogenic functions have been characterized in other malignancies35,36, its specific role in BC pathogenesis remains incompletely understood. Our results demonstrate that BD treatment significantly downregulates LRG1 expression. We propose that BD-induced FAK inhibition leads to subsequent LRG1 downregulation. This FAK-LRG1 regulatory axis represents a novel signaling pathway in BD’s antitumor mechanism, particularly in controlling cancer cell proliferation. From a translational medicine perspective, BD demonstrates promising therapeutic potential characterized by multi-mechanistic actions and favorable safety profiles. Unlike conventional single-target therapies, BD exhibits unique therapeutic advantages through its dual-pathway approach: it targets proliferative signaling via FAK/LRG1 axis inhibition while simultaneously disrupting energy metabolism by inducing mitochondrial dysfunction. Clinically used synthetic FAK inhibitors, such as defactinib37and VS-606338, are often limited by their tendency to develop rapid resistance and significant toxicity issues. In contrast, BD’s natural product origin may confer safer and more sustained antitumor efficacy with potentially reduced adverse effects. Beyond its oncological applications, BD has demonstrated efficacy in ulcerative colitis models; however, its therapeutic utility has been limited by suboptimal bioavailability. Notably, recent advances in formulation science have successfully addressed this limitation through nanoemulsion-based encapsulation, significantly improving BD’s pharmaceutical properties and overcoming a critical development barrier39. Nevertheless, several limitations must be acknowledged. The compelling in vivo results, such as those from anticancer efficacy and pharmacokinetic studies of BD, require further validation in more physiologically relevant systems to fully establish its therapeutic value. Additionally, a comprehensive characterization of BD’s pharmacokinetic profile and the optimization of its delivery strategies remain essential, alongside a deeper investigation into its complete target engagement spectrum and potential off-target interactions. In summary, our research advances the understanding of BD’s anticancer mechanisms by delineating a coordinated signaling pathway involving FAK-mediated LRG1 regulation and subsequent mitochondrial dysfunction that collectively suppresses BC cell proliferation. These findings provide a mechanistic foundation for BD’s antitumor efficacy while highlighting both the translational potential and the need for further investigation to fully realize BD’s therapeutic promise in BC treatment. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 2 Supplementary Material 3 Supplementary Material 4 Supplementary Material 5 Supplementary Material 6 Supplementary Material 7 Acknowledgements We thank Letpub (www.Letpub. com) for the linguistic assistance during the preparation of this manuscript. Abbreviations Breast Cancer Brucein D Focal Adhesion Kinase Leucine-Rich Alpha-2-Glycoprotein 1 Author contributions LL: conceptualization, methodology, validation, data curation, resources, writing—original draft preparation, and funding acquisition. SH: methodology, validation, and data curation. QY: validation and investigation. CY: validation and formal analysis. WW: conceptualization, writing-review and editing, and supervision. Funding This research was supported by the Doctoral Development Fundation of Lihuili Hospital (grant number: 2023BSKY-LL(B)). Data availability All data generated or analyzed during this study are included in this published article. Declarations Competing interests The authors declare no competing interests. Ethics approval and consent to participate Human clinical breast cancer samples were collected from the Department of Breast Surgery Ningbo Medical Center Lihuili Hospital. Patients included were all signed with an informed consent form. The research protocol was approved by the Ethical Committees of the Ningbo Medical Center Lihuili Hospital (KY2023PJ289) based on the ethical guidelines of the 1975 Declaration of Helsinki. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary Material 1 Supplementary Material 2 Supplementary Material 3 Supplementary Material 4 Supplementary Material 5 Supplementary Material 6 Supplementary Material 7 Data Availability Statement All data generated or analyzed during this study are included in this published article.